20 Years of Being Your Internet HIV/AIDS
Oral Healthcare Resource
    Click the image above to visit the CROI 2018 site directly for full webcast and workshop information.
     
 
 
Selected Presentations from CROI 2018

VIDEO: More HIV Research Highlights from CROI 2018

March 7, 2018 –HIV.gov
   
   
Cardiovascular Update CROI 2018
UCSF | May 11, 2018

Geographic Access to PrEP Clinics among US MSM: Documenting PrEP Deserts

Disparities in PrEP Uptake Among Primary Care Patients
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
CVD Factors Tied to Cognitive Impairment Differ in Women and Men With HIV
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
HIV Diagnosis After Age 50 Often Delayed Despite Clear Clues
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Comparing Strategies for Reducing Myocardial Infarction Rates in HIV Patients 
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston 
9 of 100 MSM in German Cohort Get HCV Reinfection Every Yr in DAA Era
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Low Spontaneous HCV Clearance in Big European HCV/HIV Cohort
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Methamphetamine Use Independently Predicts Premature Aging in HIV+ Individuals
CROI 2018 March 4-7 Boston, MA
New HCV Infections Still Rising Among MSM With HIV in France
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
CROI 2018: Comorbidities and Inflammation
NATAP | March 13, 2018
Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen
CROI 2018 | Hynes Convention Center | Boston, Mass | March 4-7 2018
High-Intensity Exercise Has Edge Over Moderate Intensity in Older Group With HIV - Exercise in HIV+ Improves Physical Function Impairment in HIV+ & Frailty too
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

Low Dose MK-8591 Protects Rhesus Macaques Against rectal SHIV Infection
CROI 2018 | Hynes Convention Center | Boston, Mass | March 4-7 2018

Broadly Neutralizing Antibody Treatment May Target Viral Reservoir in Monkeys
NIH | CROI 2018 | March 4, 2018
Antiretroviral Hair Levels Predict Failure in ACTG PI-Raltegravir Trial
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018

Thursday, March 1, 2018

HIV Prevention Pill not Reaching Most Americans Who Could Benefit – Especially People of Color

March 6, 2018 – CDC NCHHSTP Newsroom
Inspiring Safety and Efficacy of Dolutegravie-Based ART in TB/HIV Coinfected Adults at Week 24
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

Poorer Neurocognitive Performance Associated with CSF HIV DNA Despite Long-term ART

25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
IMPAACT P1078 at CROI 2018
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
San Francisco RAPID ART Program Halves Span From HIV Diagnosis to Suppression
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Multiple Low Doses of Nucleoside MK-8591 Strong in Healthy Volunteers
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis

25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
HIV Linked to Higher Risk of Coronary Plaque Progression in MACS Men:  “HIV Infection is Associated with Progression of Coronary Plaque: The MACS Longitudinal Coronary CT Angiography Study”    
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

SIV Rebound in the Spinal Cord After Stopping ART: A Novel CNS Reservoir

CROI 2018 March 4-7 Boston, MA
Neuroimaging Correlates of Frailty and HIV
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
The vaginal ring: more HOPE to the DREAM? Higher adherence and better effectiveness seen in ...
aidsmap | March 8, 2018
Carotid Plaque Predicts All-Cause Mortality in Women and Men With HIV: "Association of carotid artery atherosclerosis with mortality in HIV+ women and men"
Conference on Retroviruses and Opportunistic Infections (CROI), Boston, March 4-7, 2018
Lessons Learned from the Early Days of HIV/AIDS
MD Magazine | March 6, 2018

WEBCAST: Persistent Detection of HIV RNA+ Cells With ART Started in Fiebig 1 & 2 vs Fiebig 3-5

CROI 2018 March 4-7 Boston MA
Final HIV Research Highlights from CROI 2018 (2 Videos)
March 8, 2018 – HIV.gov
   
   
Female HIV acquisition per sex act is elevated in late pregnancy and postpartum
CROI 2018 March 4-7 Boston MA
Summary from CROI 2018 for viral Hepatitis HCV micro-elimination in HIV/HCV coinfection: successes and challenges
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Chronic Pain Tied to Virologic Failure, While Long-Term Opioids Lower Odds of Failure
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
ICYMI: HIV Research Round-Up from CROI 2018
HIV.gov | March 28, 2018
CDC: Clinical outcomes of US young black men with HIV receiving medical care, 2009-2014…
Combined Effects of Bisphosphonates and TDF→TAF Switch in HIV+ Adults With Low BMD
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Quantification of Replication Competent Latent HIV-1 in GALT and Semen
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Statin Use Linked to Lower Cancer Risk With or Without HIV
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
No Evidence for Ongoing HIV-1 Replication in Lymph Nodes During Suppressive ART 
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Initial HIV Load, Blips Are Strong Drivers of HIV DNA Reservoir Size
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

Antiretroviral Therapy CROI 2018 New Agents/Combinations

NATAP | March 13, 2018
Gilead Presents Results from Phase 3 Study Evaluating Patients Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) from Regimen Containing Abacavir, Dolutegravir and Lamivudine
CROI 2018 | Hynes Convention Center | Boston, Mass | March 4-7 2018
Survival Within 5 Years of Cancer Diagnosis 5 Months Shorter in People With HIV - Cancer Stage, Treatment, and Survival Comparing Hopkins HIV Clinic Enrollees and SEER.
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Integrase Inhibitor Penetration Generally Worse in Lymphoid Tissue Than Blood Cells
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Low-Dose Hydrocortisone Improves Learning and Memory in Women With HIV
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Antiretroviral Hair Levels Predict Failure in ACTG PI-Raltegravir Trial
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
One-Month Tuberculosis Prophylaxis as Effective as Nine-Month Regimen for People Living with HIV
NIH | CROI 2018 | March 5, 2018
Pharmacokinetics of Total and Unbound Darunavir in HIV-1–infected Pregnant Women Receiving a Darunavir/Cobicistat-based Regimen
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

High Uptake and Use of Vaginal Ring for HIV Prevention Observed in Open-Label Study

March 6, 2018 – NIAID Newsroom

HIV Treatment-experienced Patients Switched to D/C/F/TAF: Age, Gender, and Race Analyses

25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

Low-Dose Oral MK-8591 Protects Monkeys From Rectal SHIV Infection

25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Starting ART on Day of Home HIV Test Improves Linkage, Viral Suppression
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Statin Use Linked to Lower Cancer Risk With or Without HIV
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

Analysis of HIV Patients Switching to D/C/F/TAF by Prior ARV Treatment Experience

25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston

New Positive Data on Trogarzo™ (ibalizumab-uiyk) Injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections

25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
High HBV and HIV Suppression With Treatment of HIV/HBV Coinfection in B/F/TAF Studies
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Carotid Plaque Predicts All-Cause Mortality in Women and Men With HIV
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Progression of Coronary Plaque: The MACS Longitudinal Coronary CT Angiography Study"
Conference on Retroviruses and Opportunistic Infections (CROI), Boston, March 4-7, 2018

IMPACT OF ART REGIMENS ON CSF VIRAL ESCAPE IN HIV-1 INFECTED ADULTS

PIs, Especially Atazanavir, Linked to Detectable HIV in Cerebrospinal Fluid
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston
Asymptomatic Neurocognitive Impairment With HIV Marked by Brain Atrophy
25th Conference on Retroviruses and Opportunistic Infections (CROI), March 4-7, 2018, Boston